Have you been prescribed Docetaxel for treatment of advanced metastatic prostate cancer?
Thursday, 28th February 2019
A new radioactive labelled trace called Prostate Specific Membrane Antigen (PSMA) has been developed which is very sensitive to prostate cancer cells wherever they may be in the body.
If you have been prescribed docetaxel for treatment of advanced metastatic prostate cancer and would you be interested in taking part in a medical imaging trial that would involve having three extra scans using the PSMA alongside the usual medical imaging tests, please get in touch with Professor Barnes.
She would like to speak to you if you would be willing to:
- Discuss and answer questions about the role of nuclear medicine in your treatment;
- Discuss personal experiences with nuclear medicine tests, that you are willing to share;
- Help UCL to design a plan that includes 3 extra scans that patients would be willing to participate in.
For more detail about the trial, please view the attached article from Professor Barnes.
For information regarding eligibility criteria, and to register your interest please contact Professor Barnes directly at:
Anna Barnes, PhD, CSci, FIPEM
Clinical Scientist (PETMRI), Nuclear Medicine
HEE/NIHR-Senior Clinical Lecturer, CMI, UCL
UCL Hospitals NHS Foundation Trust
235 Euston Road | London NW1 2BU | UK
PSA Testing at Sandiway Golf Club
24 Aug 2019 11:00–15:00
Group Meeting at Leighton Hospital, Crewe
14 Sep 2019 10:00–12:00
PSA Testing at Delamere Forest Golf Club
5 Oct 2019 09:30–13:00
PSA Testing at Masonic Hall, Ellesmere Port (Closed Event)
19 Oct 2019 09:30–12:30
Group Meeting and Jacob's Table at Leighton Hospital, Crewe
9 Nov 2019 10:00–12:00